Actively Recruiting
Study to Assess Safety, Tolerability, and Body Processing of LY5625575 in Healthy Adults and Those With Elevated C-Reactive Protein
Led by Eli Lilly and Company · Updated on 2026-10-20
204
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of the drug LY5625575 in healthy adults, including Japanese and Chinese populations, as well as in participants with elevated levels of C-reactive protein, a marker for inflammation. This phase 1 study aims to understand how LY5625575 behaves in the body by measuring its presence in the bloodstream and the time it takes to be eliminated. The study is designed to last between seven and nine weeks. Participants are assigned to receive LY5625575 or a placebo orally in various dosing schedules. Some receive a single escalating dose, while others receive multiple doses. Study groups include healthy participants, those with elevated high-sensitivity C-reactive protein, healthy Japanese participants, and healthy Chinese participants. Each group has both experimental and placebo arms to compare effects. During the study, participants will undergo regular monitoring for adverse events and safety assessments up to 24 days after dosing. Researchers will also collect data on pharmacokinetics, including the concentration of LY5625575 over time. Overall participation lasts up to nine weeks, with detailed evaluations to understand the drugs safety, tolerability, and body processing in different populations.
CONDITIONS
Brief Title
A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here